MIOCAMEN 600MG TABLET

Dosage

Children: Diacetyl does not have established pediatric dosing guidelines as it is not commonly used therapeutically.

Adults: Diacetyl is not typically used as a medication in adults, thus specific dosing guidelines are not available.

Mechanism of action

Diacetyl acts by influencing metabolic pathways associated with fermentation and flavor production, particularly in the biosynthesis of compounds like myricetin gentiobioside and kaempferol gentiobioside. It is involved in the superpathway of heme biosynthesis from glycine and participates in pyruvate metabolism, converting pyruvate into acetoin, which can affect microbial growth and flavor profiles.

Pharmacodynamics

Diacetyl possesses flavoring properties and may influence the sensory characteristics of food products. Its effects in biological systems are linked to its role in fermentation and metabolic processes, though specific pharmacodynamic effects in humans are not well established due to limited clinical use.

Pharmacokinetics

The pharmacokinetics of diacetyl have not been extensively studied, as it is primarily recognized for its flavoring properties rather than therapeutic use. Its absorption, distribution, metabolism, and excretion in humans are not well-defined, and further research is needed to elucidate these parameters.

Pregnancy

There is insufficient data on the use of diacetyl in pregnant women to establish safety. Caution is advised.

Breast-feeding

There is limited information on the excretion of diacetyl in human milk. Caution is recommended when used during breastfeeding.

Storage

Store in a cool, dry place away from light. Ensure containers are tightly closed.

Indications

• Bacterial infections of the respiratory tract
• Skin infections
• Soft tissue infections
• Other infections caused by susceptible Gram-positive bacteria

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines in paediatric patients.

Adults: Refer to the BNF for specific dosing recommendations based on the type of infection being treated.

Mechanism of action

Midecamycin inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit. This action prevents peptide bond formation and translocation during the protein synthesis process. Mutations in the 50S RNA can hinder midecamycin's ability to bind effectively, which may lead to resistance.

Pharmacodynamics

Midecamycin demonstrates activity against Gram-positive organisms and is effective against both erythromycin-susceptible and efflux-mediated erythromycin-resistant strains. The diacetate form of midecamycin enhances its pharmacokinetic profile and reduces gastrointestinal side effects. Its activity is optimized at pH 7-8, and it has a longer half-life compared to other formulations.

Pharmacokinetics

Midecamycin is absorbed after oral administration, and its pharmacokinetics are improved in the diacetate form, which also mitigates gastrointestinal side effects. The drug has a prolonged half-life, providing sustained antibacterial activity. The specific absorption, distribution, metabolism, and excretion parameters are detailed in clinical pharmacology references.

Pregnancy

Midecamycin should be used during pregnancy only if clearly needed, as there is limited data on its safety in pregnant women.

Breast-feeding

Midecamycin is excreted in breast milk; caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Tablets
• Suspensions

Mechanism of action

Midecamycin, as part of the macrolides, act by inhibiting bacterial protein synthesis. More specifically, midecamycin inhibits bacterial growth by targetting the 50S ribosomal subunit preventing peptide bond formation and translocation during protein synthesis. The presence of mutations in the 50S RNA can prevent midecamycin binding. Midecamycin is a broad spectrum antibiotic and thus, it can interact with different bacteria.

Pharmacodynamics

Reports have indicated that midecamycin is active against both erythromycin-susceptible and efflux-mediated erythromycin-resistant strains. The diacetate form of this product reduces gastrointestinal side effects and improves its pharmacokinetic profile. Studies have proved that midecamycin is highly active against Gram-positive organisms. The activity of midecamycin in the form of acetate salt presents a better activity, which seems to be potentiated at pH 7-8, as well as a longer half-life.